JonnyFinlay (@finlay_jonny) 's Twitter Profile
JonnyFinlay

@finlay_jonny

LockBody Tx (A @Centessa Company), Granular Tx (An AlysPharma.com company), ottimopharma.com and Rxbiologics.co.uk Views are my own.

ID: 757807244

calendar_today14-08-2012 20:10:52

8,8K Tweet

698 Followers

899 Following

Medicxi (@medicxi) 's Twitter Profile Photo

🚀 Congratulations to Alys Pharmaceuticals on advancing its first intradermally administered siRNA for immune-dermatology into the clinic! The Phase 2a will evaluate the safety & efficacy of ALY-101, a JAK1-targeted siRNA in patients with alopecia areata alyspharma.com/alys-pharmaceu…

John E. Harris, MD, PhD (@harrisvitiligo) 's Twitter Profile Photo

Proud of my colleagues at Alys Pharma for achieving IND clearance to start Phase 2a trial of intradermal siRNA targeting JAK1 to treat alopecia areata! Major milestone in advancing RNA Therapeutics in dermatology and the first of many in our pipeline alyspharma.com/alys-pharmaceu…

Andrea C. Love, PhD (@dr_andrealove) 's Twitter Profile Photo

Vaccines don’t cause autism. Vaccines aren’t even associated with autism. The biggest predictor of autism? GENETICS. We have decades of data and millions of data points that to show this. This lie insults people with autism too — as if it’s an “adverse effect” of medicine.

RxCelerate (@rxcelerate) 's Twitter Profile Photo

Day 1 @ #NextGenBiomed2025 Visit our Booth (22) or poster to learn about our bespoke antibody discovery services, from our Galaxy® antibody discovery platform to in silico modelling. & grab one of our #phage or #bispecific pins! 🔗rxbiologics.com 📩[email protected]

Day 1 @ #NextGenBiomed2025

Visit our Booth (22) or poster to learn about our bespoke antibody discovery services, from our Galaxy® antibody discovery platform to in silico modelling.

& grab one of our #phage or #bispecific pins!

🔗rxbiologics.com
📩info@rxbiologics.com
Anon Opin. (@anon_opin) 's Twitter Profile Photo

The British public refuse to accept that it's cheaper to provide welfare than withdraw it. Fewer benefits result in increased crime and poorer public health, requiring increased resources for the police and NHS. Prevention is cheaper than the cure, it's that fucking simple.

RxCelerate (@rxcelerate) 's Twitter Profile Photo

We’ve formed the RxBiologics SAB, bringing together leaders in antibody discovery to help guide innovation and strategy. Joining Jonny Finlay are experts from Diagonal Therapeutics, Curie.Bio, Merck, and Granular Therapeutics. 🔗 Read more: rxcelerate.com/rxbiologics-sc…

We’ve formed the RxBiologics SAB, bringing together leaders in antibody discovery to help guide innovation and strategy.

Joining Jonny Finlay are experts from Diagonal Therapeutics, Curie.Bio, Merck, and Granular Therapeutics.

🔗 Read more: rxcelerate.com/rxbiologics-sc…
Lance Lachlan ✌🏻 (@lancelachlan) 's Twitter Profile Photo

The true goals of Brexit? 1.Make the UK population poorer. 2.Weaken the UK on the international stage. 3.Render the UK irrelevant in global affairs. 4.Avoid EU-wide tax transparency so the British elite could keep hiding their money. Brexit has completely failed. We’re all

Brian S. Kim (@itchdoctor) 's Twitter Profile Photo

Sanofi makes $9.5B acquisition of Blueprint which develops c-Kit blocking Rx. Our company, Alys Pharma has developed next gen Rx for c-Kit blocking with biSAb. This field is 🔥. Medicxi ca.finance.yahoo.com/news/sanofi-bu…

JonnyFinlay (@finlay_jonny) 's Twitter Profile Photo

Welcome to the world ALY-301. When we designed this molecule we aimed to provide the very first truly mast cell-selective KIT inhibitory bispecific. It's a joy to see that aim fulfilled. Off to the clinic John E. Harris, MD, PhD Brian S. Kim Medicxi alyspharma.com/alys-pharmaceu…

Brian S. Kim (@itchdoctor) 's Twitter Profile Photo

Our 2nd drug to the clinic! this time Alys Pharma is bringing a bispecific Ab directed at c-Kit and CD203c to selectively target pathogenic, activated mast cells. I am so very proud of this team! JonnyFinlay John E. Harris, MD, PhD Medicxi. These therapies promise to transform

Our 2nd drug to the clinic! this time Alys Pharma is bringing a bispecific Ab directed at c-Kit and CD203c to selectively target pathogenic, activated mast cells. I am so very proud of this team! <a href="/Finlay_Jonny/">JonnyFinlay</a> <a href="/HarrisVitiligo/">John E. Harris, MD, PhD</a> <a href="/medicxi/">Medicxi</a>. 

These therapies promise to transform
Dermatology Times (@dermtimesnow) 's Twitter Profile Photo

❗Alys Pharmaceuticals filed to begin clinical trials of ALY-301, a first-in-class, mast cell–selective c-Kit inhibitor for cold #urticaria. hubs.li/Q03sNcGw0 #DermTwitter

JonnyFinlay (@finlay_jonny) 's Twitter Profile Photo

Could not agree more. Life as an academic is not easy at all. Making truly great scientific discoveries is extremely difficult and should be celebrated, but Making a successful drug is one of the toughest things one can ever hope to do in science....

Steve Jurvetson (@futurejurvetson) 's Twitter Profile Photo

Smash the mutants 🦠 to end the pandemic era for humanity — with a single shot for all flu and then coronaviruses, HIV, herpes, malaria, cancer and more! These scourges have evaded effective vaccines because they continuously mutate their outer epitopes to evade our immune

Smash the mutants  🦠  to end the pandemic era for humanity
 — with a single shot for all flu and then coronaviruses, HIV, herpes, malaria, cancer and more!  These scourges have evaded effective vaccines because they continuously mutate their outer epitopes to evade our immune
David Grainger (@sciencescanner) 's Twitter Profile Photo

What a spectacular achievement! Congratulations to the whole Medicxi team - but most of all to Vanni Mariggi who has tirelessly supported Vicebio from inception to exit. These are the kind of deals that create legendary VCs!